The resolution of Expert Board meeting «Advanced stage of Parkinson’s disease. Possibilities of the transition to non-invasive methods of treatment». Moscow. Dec16 2016

doi:https://doi.org/10.17116/jnevro201711751117-118

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(5): 117‑118

DOI: 10.17116/jnevro201711751117-118

Read: 814 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

The resolution of Expert Board meeting «Advanced stage of Parkinson’s disease. Possibilities of the transition to non-invasive methods of treatment». Moscow. Dec16 2016. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(5):117‑118. (In Russ.)
https://doi.org/10.17116/jnevro201711751117-118

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

References:

Wirdefeldt K, Adami HO, Cole P et al. Epidemiology and etiology of Parkinson’s disease. Eur J Epidemiol. 2011;26:1-58.
Spottke AE, Reuter M, Machat O et al. Cost of illness and its predictors for Parkinson’s disease in Germany. Pharmaco Economics. 2005;23:817-836.
Vossius C, Gjerstad M, Baas H, Larsen JP. Drug costs for patients with Parkinson’s disease in two different European countries. Acta Neurol Scand. 2006;113:228-232.
von Campenhausen S, Winter Y, Rodrigues Silva A et al. Costs of illness and care in Parkinson’s disease: an evaluation in six countries. Eur Neuropsychopharmacol. 2011;21:180-191.
Jenner P. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J Neurol. 2000;247(suppl 2):43-50.
Poewe W. The natural history of Parkinson’s disease. J Neurol. 2006;253(suppl 7):2-6.
Schapira A. Present and future drug treatment for Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2005;76:1472-1478.
Krames ES, Peckham PH, Rezai AR (eds.). Neuromodulation. Academic Press. 2009;1-2.
Dallapiazza R, McKisic MS, Shah B, Elias WJ. Neuromodulation for movement disorders. Neurosurg Clin N Am. 2014;25:47-58.
Aquilonius S-M, Mouradian MM. Parkinson’s disease: Role of continuous dopaminergic stimulation. Crowthorne: ESP Bioscience; 2012.
Kristiansen IS, Bingefors K, Nyholm D, Isacson D. Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson’s disease in Sweden: an exploratory study. Appl Health Econ Health Policy. 2009;7:167-180.
Lowin J, Bergman A, Chaudhuri KR et al. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson’s diseases in the UK. J Med Econ. 2011;14:584-593.
Antonini A, Odin P, Kleinman L et al. Implementing a Delphi Panel to Improve Understanding of Patient Characteristics of Advanced Parkinson’s Disease. Mov Disord. 2015;30:1186. Presented at the 19th International Congress of Parkinson’s Disease and Movement Disorders. San Diego, California, United States. 2015.
Fernandez H, Standaert D, Hauser RA et al. Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: Final 12-Month, Open-Label Results. Mov Disord. 2015;30:500-508.